NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19

NIAID is supporting a set of adaptive treatment studies for COVID-19, part of the ACTIV public-private partnership, which are designed to test a variety of therapeutics with speed and flexibility. ACTIV-2 will begin by testing a monoclonal antibody treatment in volunteers with mild and moderate cases of the disease, who do not require hospitalization. Additional investigational therapeutics may be tested later in this study.